
REUN
Healthcare · Biotechnology · $13.0M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2023
EPS trend, 90 days to now · +67.9% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 13, 2023 | Time not confirmed | -0.30 | 0.00 | +100.0% |
| Aug 15, 2023 | Time not confirmed | -0.29 | 0.00 | +100.0% |
| Jun 27, 2023 | After the close | -0.61 | -0.55 | +9.8% |
| Feb 14, 2023 | Before the open | -0.44 | -1.07 | -143.2% |
| Nov 13, 2022 | After the close | -0.28 | -1.38 | -392.9% |
| Aug 15, 2022 | After the close | -1.00 | -0.23 | +77.0% |
| Jun 28, 2022 | After the close | -1.13 | -1.20 | -6.2% |
| Feb 14, 2022 | After the close | -1.01 | -1.30 | -28.7% |
| Nov 14, 2021 | After the close | -0.92 | -1.15 | -25.0% |
| Aug 16, 2021 | After the close | -0.65 | -1.10 | -69.2% |
| Jun 24, 2021 | After the close | -0.65 | -0.90 | -38.5% |
| Feb 16, 2021 | After the close | -0.55 | -1.10 | -100.0% |
| Oct 23, 2020 | After the close | — |
Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. The company's lead asset includes RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It is also developing the RE200 series, which comprises molecules that are structurally designed to be similar to classical…
| -4.74 |
| — |